Circ_0012152 Accelerates Acute Myeloid Leukemia Progression through the miR-652-3p/SOX4 Axis

Abstract

Objective

Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by abnormal myeloid blast expansion. Recent studies have demonstrated that circular RNAs play a role in AML pathogenesis. In this study, we aimed to investigate the clinical significance of circ_0012152 in AML and elucidate its underlying molecular mechanism in the pathogenesis of this condition.

Methods

Circ_0012152 expression was detected by quantitative real-time polymerase chain reaction in samples obtained from 247 patients with AML and 40 healthy controls. A systematic analysis of clinical characteristics and prognostic factors was also conducted. Cell growth was assessed using the Cell Counting Kit-8 (CCK-8) assay, and apoptosis and cell cycle progression were evaluated by flow cytometry. Moreover, RNA pull-down was performed to identify target microRNAs, and transcriptome RNA sequencing and bioinformatics analyses were utilized to identify downstream mRNA targets.

Results

Circ_0012152 was significantly upregulated in samples from patients with AML and served as an independent adverse prognostic factor for overall survival (OS) (hazard ratio: 2.357; 95% confidence interval 1.258–4.415). The circ_0012152 knockdown reduced cell growth, increased apoptosis, and inhibited cell cycle progression in AML cell lines. RNA pull-down and sequencing identified miR-652-3p as a target microRNA of circ_0012152. Cell growth inhibition by circ_0012152 knockdown was significantly relieved by miR-652-3p inhibitors. We suggested that miR-652-3p targeted SOX4, as the decrease in SOX4 expression resulting from circ_0012152 knockdown was upregulated by miR-652-3p inhibitors in AML cells.

Conclusion

Circ_0012152 is an independent poor prognostic factor for OS in AML, and it promotes AML cell growth by upregulating SOX4 through miR-652-3p.

References

[1] PapaemmanuilE, GerstungM, BullingerL, et al.. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med, 2016, 374(23): 2209-2221

[2] BurnettA, StoneR. AML: New Drugs but New Challenges. Clin Lymphoma Myeloma Leuk, 2020, 20(6): 341-350

[3] TholF, GanserA. Treatment of Relapsed Acute Myeloid Leukemia. Curr Treat Options Oncol, 2020, 21(8): 66

[4] CumminsKD, GillS. Will CAR T-cell therapy have a role in AML? Promises and pitfalls. Seminars in hematol, 2019, 56(2): 155-163

[5] FennellKA, BellCC, DawsonMA. Epigenetic therapies in acute myeloid leukemia: where to from here?. Blood, 2019, 134(22): 1891-1901

[6] KumarS, GonzalezEA, RameshwarP, et al.. Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies. Cancers (Basel), 2020, 12(12): 3657

[7] JeckWR, SorrentinoJA, WangK, et al.. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 2013, 19(2): 141-157

[8] VerduciL, StranoS, YardenY, et al.. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol Oncol, 2019, 13(4): 669-680

[9] LiA, WangWC, McAlisterV, et al.. Circular RNA in colorectal cancer. J Cell Mol Med, 2021, 25(8): 3667-3679

[10] LeiB, TianZ, FanW, et al.. Circular RNA: a novel biomarker and therapeutic target for human cancers. Int J Med Sci, 2019, 16(2): 292-301

[11] FuL, TangD, SunA, et al.. Recent progress in study of circRNAs and its role in leukemia. J Leukoc Biol, 2021, 109(4): 731-739

[12] DingY, DongY, LuH, et al.. Circular RNA profile of acute myeloid leukemia indicates circular RNA annexin A2 as a potential biomarker and therapeutic target for acute myeloid leukemia. Am J Transl Res, 2020, 12(5): 1683-1699

[13] HuQ, GuY, ChenS, et al.. Hsa_circ_0079480 promotes tumor progression in acute myeloid leukemia via miR-654-3p/HDGF axis. Aging (Albany NY), 2020, 13(1): 1120-1131

[14] ZhouX, ZhanL, HuangK, et al.. The functions and clinical significance of circRNAs in hematological malignancies. J Hematol Oncol, 2020, 13(1): 138

[15] LiW, ZhongC, JiaoJ, et al.. Characterization of hsa_circ_0004277 as a New Biomarker for Acute Myeloid Leukemia via Circular RNA Profile and Bioinformatics Analysis. Int J Mol Sci, 2017, 18(3): 597

[16] Rybak-WolfA, StottmeisterC, GlažarP, et al.. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. Mol Cell, 2015, 58(5): 870-885

[17] KristensenLS, HansenTB, VenøMT, et al.. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene, 2018, 37(5): 555-565

[18] LiZ, HuangC, BaoC, et al.. Exon–intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol, 2015, 22(3): 256-264

[19] GuoS, LiB, ChenY, et al.. Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia. Front Oncol, 2020, 10(1655): 1-13

[20] ShangZ, MingX, WuJ, et al.. Downregulation of circ_0012152 inhibits proliferation and induces apoptosis in acute myeloid leukemia cells through the miR-625-5p/SOX12 axis. Hematol Oncol, 2021, 39(4): 539-548

[21] LiuX, LiuX, CaiM, et al.. CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia. Mol Cancer, 2021, 20(1): 139

[22] ZhangZ, LinS, YinJ, et al.. CircRNF220 plays a pathogenic role to facilitate cell progression of AML in vitro by sponging miR-330-5p to induce upregulation of SOX4. Histol Histopathol, 2022, 37(10): 1019-1030

[23] BatallerA, GarridoA, GuijarroF, et al.. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv, 2022, 6(4): 1193-1206

[24] De KouchkovskyI, Abdul-HayM. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J, 2016, 6(7): e441

[25] LevisM. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?. Hematology Am Soc Hematol Educ Program, 2013, 2013: 220-226

[26] NicoletBP, EngelsS, AglialoroF, et al.. Circular RNA expression in human hematopoietic cells is widespread and cell-type specific. Nucleic Acids Res, 2018, 46(16): 8168-8180

[27] ZhangF, JiangJ, QianH, et al.. Exosomal circRNA: emerging insights into cancer progression and clinical application potential. J Hematol Oncol, 2023, 16(1): 67

[28] ZhouB, MoZ, LaiG, et al.. Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-κB-IL-6 axis of tumor-associated macrophages. J Exp Clin Cancer Res, 2023, 42(1): 48

[29] SunX, DongolS, QiuC, et al.. miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer. Mol Cancer Res, 2018, 16(12): 1927-1939

[30] ChaoY, YangC, XiongW, et al.. miR-652 Inhibits the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting HOXA9 and Regulating the PI3K/Akt Signaling Pathway. J Oncol, 2022, 2022: 4809312

[31] JiangQ, LuX, HuangP, et al.. Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. Biomed Res Int, 2018, 2018: 5724686

[32] ZhangJ, XiaoC, FengZ, et al.. SOX4 promotes the growth and metastasis of breast cancer. Cancer Cell Int, 2020, 20: 468

[33] LuJW, HsiehMS, HouHA, et al.. Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish. Blood Cancer J, 2017, 7(8): e593

[34] GruszkaAM, ValliD, AlcalayM. Wnt Signaling in Acute Myeloid Leukemia. Cells, 2019, 8(11): 1403

[35] TickenbrockL, SchwäbleJ, WiedehageM, et al.. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood, 2005, 105(9): 3699-3706

[36] MorenoCS. SOX4: The unappreciated oncogene. Semin Cancer Biol, 2020, 67: 57-64 Pt 1)

[37] QuY, WangY, WangP, et al.. Overexpression of long noncoding RNA HOXA-AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia. Cell Biol Int, 2020, 44(8): 1745-1759

[38] MehtaGA, ParkerJS, SilvaGO, et al.. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Res Treat, 2017, 162(3): 439-450

[39] Ramezani-RadP, GengH, HurtzC, et al.. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood, 2013, 121(1): 148-155